Management of Von Hippel-Lindau Disease

Diagnosis and Surveillance

• Genetic testing is the gold standard for VHL diagnosis and should be performed in all first-degree relatives of individuals with pathogenic VHL variants, as recommended by the National Comprehensive Cancer Network 1
• Clinical diagnosis can be established in individuals with a family history of VHL who have CNS/retinal hemangioblastoma, pheochromocytoma, or renal cell carcinoma, with a strength of evidence level of high 2
• The American College of Medical Genetics recommends genetic testing for any child diagnosed with retinal angioma/hemangioblastoma, CNS hemangioblastoma, clear cell renal cell carcinoma, pheochromocytoma or paraganglioma, endolymphatic sac tumor, epididymal/adnexal papillary cystadenoma, multiple pancreatic cysts or neuroendocrine tumors, or multiple renal cysts 1

Surveillance Recommendations

• The American Academy of Ophthalmology recommends beginning ocular screening within 12 months after birth and continuing throughout life, with examinations every 6-12 months until age 30, then at least yearly thereafter 3
• The National Institute of Neurological Disorders and Stroke recommends beginning CNS imaging at age 8 years, with early detection of CNS hemangioblastomas allowing surgical excision with minimal damage to surrounding tissue 1
• The American Urological Association recommends beginning abdominal imaging at age 8-10 years, with annual abdominal imaging (alternating ultrasound and MRI) starting at age 16, to monitor for renal cysts and renal cell carcinoma 1
• The Endocrine Society recommends beginning screening for pheochromocytoma at age 5 years with annual plasma or urine metanephrines, with a strength of evidence level of moderate 1, 4

Treatment Approaches

• The National Comprehensive Cancer Network recommends surgical intervention as the mainstay of treatment for most VHL-related tumors, with retinal hemangioblastomas being treated promptly to prevent vision loss 3
• The American Association of Neurological Surgeons recommends surgically excising CNS hemangioblastomas when detected early, to minimize damage to surrounding tissue 1

Multidisciplinary Approach

• The National Cancer Institute recommends management involving specialists in ophthalmology, neurosurgery, urology/nephrology, endocrinology, medical genetics, and oncology, with patients being managed at centers capable of providing multiorgan surveillance and access to genetic testing 1, 3, 5

Prognosis and Follow-up

• The National Institute of Health recommends lifelong surveillance, given ongoing risks for tumor development with increasing age, with early recognition and intervention limiting morbidity and mortality in VHL 1
• The American College of Medical Genetics notes that up to 20% of VHL cases arise from de novo mutations, so absence of family history does not rule out the diagnosis, with a strength of evidence level of high 5

Management of Von Hippel-Lindau Disease

Treatment Approach by Manifestation

• The American Academy of Ophthalmology recommends that extramacular or extrapapillary retinal hemangioblastomas should be treated immediately, even when small (≤500 μm in diameter), to prevent vision loss 6, 7
• Laser photocoagulation achieves successful destruction in 100% of retinal hemangioblastomas ≤1.5 mm in diameter, compared to only 47-73% of larger lesions 6, 7, 8
• Early treatment before symptoms appear maintains good vision 6, 8
• Spontaneous regression is rare and tumor growth is unpredictable, making close observation not recommended 6, 9, 10
• For juxtrapapillary or macular lesions where laser ablation is risky, consider belzutifan as a safer alternative 6, 7, 8

Systemic Emerging Therapy

• Belzutifan, an oral HIF-2α inhibitor, represents a significant advance approved by the FDA for multiple manifestations of VHL 6, 7, 8
• It avoids direct damage from local ablation, providing a safer option for juxtrapapillary, macular, or large tumors 6, 7, 8
• It may allow for earlier treatment of tumors without ablative therapies 6, 8
• It could have a role in suppressing the formation of retinal hemangioblastomas 6, 8
• Clinical experience with this agent continues to expand 6, 7, 8

Essential Surveillance Program

• Surveillance should start within the first 12 months of life and continue for life, as tumor development can occur at any age 11
• The American Academy of Pediatrics recommends ophthalmologic examination every 6-12 months from birth to 30 years, and at least annually after 30 years 11
• The National Comprehensive Cancer Network recommends imaging of the central nervous system starting at 8 years of age, and abdominal imaging starting at 8-10 years, with annual images (alternating ultrasound and MRI) from 16 years 11

Management Considerations

• Patients should be managed by specialists with experience in VHL, ideally within a multidisciplinary center capable of providing multi-organ surveillance and access to genetic testing 11, 12
• A multidisciplinary team including ophthalmology, neurosurgery, urology/nephrology, endocrinology, medical genetics, and oncology is required for optimal management 11, 12

Management and Surveillance of Von Hippel‑Lindau (VHL) Manifestations

Retinal Hemangioblastoma Characteristics

Treatment Recommendations for Retinal Hemangioblastomas

Associated Non‑Retinal Tumors in VHL

Multidisciplinary Care and Surveillance